Content
Search
Navigation
Sitemap

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Cell therapy companies
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Neogene Therapeutics
Clade Therapeutics
all Gene therapy companies
Freeline Therapeutics
SwanBio Therapeutics
Purespring Therapeutics
all Biologics companies
Anaveon
all Small molecule companies
OMass Therapeutics

06.10.22

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Operating News
Cell therapy
Achilles Therapeutics

09.08.22

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Operating News
Cell therapy
Achilles Therapeutics

21.07.22

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Cell therapy
Achilles Therapeutics

30.06.22

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Operating News
Cell therapy
Achilles Therapeutics

21.06.22

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

Cell therapy
Achilles Therapeutics

10.05.22

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

Cell therapy
Achilles Therapeutics

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and Insights
Investors
Contact

Copyright © Syncona 2022
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay

About us
Our people
- Our people
- Board of directors
Portfolio
Sustainability
News and Insights
Investors
Contact

GBX 181.80

Change: -1.60 (-0.87%)

Search

Search